VEPH1 is an evolutionarily conserved adaptor protein that negatively regulates multiple signaling pathways critical to cancer progression and development 1. Its primary function involves inhibiting TGF-β signaling by interacting with TGFBR1 and preventing SMAD2 nuclear accumulation 2, though it also modulates FOXO, Hippo, and Wnt signaling pathways 1. Mechanistically, VEPH1 operates through diverse protein-protein interactions. It binds directly to TSC1/TSC2 complexes, enhancing their association and promoting mTORC1 pathway inhibition 3. Additionally, VEPH1 interacts with ERBB2's kinase domain to modulate EGF signaling 4, and associates with androgen receptor to suppress SMAD3 and AKT activation in ovarian cancer 5. Through AKT inhibition, VEPH1 decreases VEGFA and IL8 expression, reducing tumor vascularization 6. VEPH1 frequently shows reduced expression in hepatocellular carcinoma and cutaneous melanoma, correlating with poor prognosis and aggressive phenotypes 32. In melanoma, VEPH1 overexpression suppresses epithelial-mesenchymal transition and tumor progression 2. Recent evidence implicates VEPH1 hypomethylation in developmental language disorder through Wnt signaling dysregulation 7, expanding its role beyond cancer biology.